ITEM VIEW

The 5-year outcome of multidrug resistant tuberculosis patients in the Cape Province of South Africa

dc.contributor.authorSchaaf H.S.
dc.contributor.authorBotha P.
dc.contributor.authorBeyers N.
dc.contributor.authorGie R.P.
dc.contributor.authorVermeulen H.A.S.
dc.contributor.authorGroenewald P.
dc.contributor.authorCoetzee G.J.
dc.contributor.authorDonald P.R.
dc.date.accessioned2011-05-15T16:18:17Z
dc.date.available2011-05-15T16:18:17Z
dc.date.issued1996
dc.identifier.citationTropical Medicine and International Health
dc.identifier.citation1
dc.identifier.citation5
dc.identifier.issn13602276
dc.identifier.urihttp://hdl.handle.net/10019.1/14593
dc.description.abstractLittle is known about the outcome of multidrug resistant (MDR) tuberculosis (TB) in developing countries. In this study, 443 patients with MDR-TB, defined as resistance to two Or more antituberculosis drugs, were identified over the 2-year period 1987 and 1988 in the Cape Province of South Africa. The 5-year outcome of the 343 (77%) patients that could be traced by questionnaire was evaluated retrospectively during 1992 and 1993 Of these, 240 (70%) were resistant to both isoniazid (H) and rifampicin (R) with or without resistance to other first-line antituberculosis drugs and 103 (30%) were resistant to H or R and/or other antituberculosis drugs. Mortality was 116 (48%) and 28 (27%) in these groups respectively with a significantly greater risk of death in the first group. Only 114 (33%) of all the MDR-TB patients were cured after 5 years, 50 (15%) were respiratory disabled and 44 (13%) were still bacteriology positive. Twenty-four (7%) patients were lost during follow-up. Taking into account the high costs involved in treating MDR-TB patients and the scarce resources available in developing countries, more emphasis should be placed on direct observed therapy to cure newly diagnosed infectious drug sensitive tuberculosis patients, thus preventing MDR-TB rather than treating it.
dc.subjectethambutol
dc.subjectethionamide
dc.subjectisoniazid
dc.subjectpyrazinamide
dc.subjectrifampicin
dc.subjectstreptomycin
dc.subjectarticle
dc.subjectcontrolled study
dc.subjectdrug cost
dc.subjectdrug efficacy
dc.subjecthuman
dc.subjectlung tuberculosis
dc.subjectmajor clinical study
dc.subjectmorbidity
dc.subjectmortality
dc.subjectmycobacterium tuberculosis
dc.subjectsouth africa
dc.subjecttreatment outcome
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectAntitubercular Agents
dc.subjectFemale
dc.subjectHumans
dc.subjectIsoniazid
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectMycobacterium tuberculosis
dc.subjectOutcome Assessment (Health Care)
dc.subjectPyrazinamide
dc.subjectQuestionnaires
dc.subjectRetrospective Studies
dc.subjectRifampin
dc.subjectSouth Africa
dc.subjectTime Factors
dc.subjectTuberculosis, Multidrug-Resistant
dc.subjectMycobacterium
dc.subjectMycobacterium tuberculosis
dc.titleThe 5-year outcome of multidrug resistant tuberculosis patients in the Cape Province of South Africa
dc.typeArticle
dc.description.versionArticle


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

ITEM VIEW